Predicted protein targets (top 16)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | EGFR | P00533 | 1/20 | 0.41 |
| ▸ | SRC | P12931 | 1/20 | 0.41 |
| ▸ | ELANE | P08246 | 12/20 | 0.39 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | F2 | P00734 | 4/20 | 0.37 |
| ▸ | PLAU | P00749 | 4/20 | 0.37 |
| ▸ | CNR2 | P34972 | 2/20 | 0.36 |
| ▸ | CNR1 | P21554 | 1/20 | 0.36 |
| ▸ | POLB | P06746 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | PGR | P06401 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | PDE4A | P27815 | 1/20 | 0.34 |
| ▸ | PDE4B | Q07343 | 1/20 | 0.34 |
| ▸ | PDE4C | Q08493 | 1/20 | 0.34 |
| ▸ | PDE4D | Q08499 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23940247 | 0.80 | KDM4E (0.57) | EGFRSRCELANEKDM4EF2 | |
| SCHEMBL23940253 | 0.73 | KDM4E (0.42) | ELANEKDM4EF2PLAUCNR2 | |
| SCHEMBL23940218 | 0.72 | ATM (0.58) | KDM4EMEN1KMT2A | |
| SCHEMBL26564649 | 0.72 | PDE4A (0.37) | ELANEKDM4ECNR2POLBMEN1 | |
| SCHEMBL12575030 | 0.70 | GLS (0.47) | ELANEKDM4ECNR2POLBPDE4A | |
| SCHEMBL14584166 | 0.69 | RORC (0.55) | — | |
| SCHEMBL4420492 | 0.68 | PRKD3 (0.43) | SRCKDM4ECNR2PDE4APDE4B | |
| SCHEMBL14584040 | 0.68 | PDE4A (0.37) | SRCKDM4ECNR2POLBMEN1 | |
| SCHEMBL27249849 | 0.68 | KDM4E (0.48) | KDM4E | |
| SCHEMBL31560837 | 0.67 | ELANE (0.46) | ELANEKDM4EMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 1 patent. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | BRISTOL-MYERS SQUIBB COMPANY (US) | 2021-10-21 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20210323966-A1 | IMIDAZOPYRIDAZINE COMPOUNDS | TYK2, JAK3, JAK1 | EGFR 2340/4885SRC 369/4885ELANE 3295/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.